Brokerages Expect Hologic, Inc. (NASDAQ:HOLX) Will Post Quarterly Sales of $1.02 Billion

Analysts expect that Hologic, Inc. (NASDAQ:HOLX) will post $1.02 billion in sales for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Hologic’s earnings, with the lowest sales estimate coming in at $1.01 billion and the highest estimate coming in at $1.03 billion. Hologic reported sales of $1.35 billion during the same quarter last year, which suggests a negative year-over-year growth rate of 24.4%. The company is scheduled to report its next quarterly earnings results after the market closes on Monday, November 1st.

According to Zacks, analysts expect that Hologic will report full-year sales of $5.34 billion for the current year, with estimates ranging from $5.32 billion to $5.36 billion. For the next year, analysts expect that the company will report sales of $3.91 billion, with estimates ranging from $3.80 billion to $4.14 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Hologic.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, July 28th. The medical equipment provider reported $1.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.21. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.03 billion. Hologic had a net margin of 35.98% and a return on equity of 67.74%. During the same period last year, the firm posted $0.75 earnings per share.

A number of brokerages have recently issued reports on HOLX. Raymond James raised their target price on shares of Hologic from $78.00 to $88.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 3rd. Evercore ISI upgraded shares of Hologic from an “in-line” rating to an “outperform” rating and set a $78.00 target price on the stock in a research report on Tuesday, July 6th. Morgan Stanley decreased their price target on Hologic from $77.00 to $75.00 and set an “equal weight” rating for the company in a report on Friday, July 30th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Friday, July 30th. Finally, Zacks Investment Research raised Hologic from a “strong sell” rating to a “hold” rating and set a $71.00 price target for the company in a report on Tuesday, June 29th. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, Hologic currently has a consensus rating of “Buy” and an average target price of $85.50.

Institutional investors have recently made changes to their positions in the company. IndexIQ Advisors LLC lifted its holdings in shares of Hologic by 3.3% during the second quarter. IndexIQ Advisors LLC now owns 4,210 shares of the medical equipment provider’s stock valued at $281,000 after purchasing an additional 135 shares during the last quarter. CX Institutional lifted its holdings in shares of Hologic by 38.1% during the second quarter. CX Institutional now owns 602 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 166 shares during the last quarter. Lido Advisors LLC lifted its holdings in shares of Hologic by 3.5% during the first quarter. Lido Advisors LLC now owns 5,086 shares of the medical equipment provider’s stock valued at $378,000 after purchasing an additional 170 shares during the last quarter. Rockefeller Capital Management L.P. lifted its holdings in shares of Hologic by 2.0% during the first quarter. Rockefeller Capital Management L.P. now owns 8,682 shares of the medical equipment provider’s stock valued at $645,000 after purchasing an additional 171 shares during the last quarter. Finally, Cutter & CO Brokerage Inc. lifted its holdings in shares of Hologic by 1.8% during the second quarter. Cutter & CO Brokerage Inc. now owns 9,965 shares of the medical equipment provider’s stock valued at $665,000 after purchasing an additional 175 shares during the last quarter. Institutional investors and hedge funds own 91.84% of the company’s stock.

Shares of HOLX traded up $0.33 during mid-day trading on Wednesday, reaching $70.16. 927,575 shares of the company’s stock were exchanged, compared to its average volume of 2,051,037. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.65 and a quick ratio of 1.31. The stock has a market capitalization of $17.78 billion, a PE ratio of 8.99, a price-to-earnings-growth ratio of 0.69 and a beta of 1.17. The business’s fifty day simple moving average is $76.39 and its 200-day simple moving average is $71.04. Hologic has a 52-week low of $60.10 and a 52-week high of $85.00.

Hologic Company Profile

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.

Featured Article: Determine Your Level of Risk Tolerance

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.